Redhill

RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published

Retrieved on: 
Monday, November 14, 2022

The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.

Key Points: 
  • The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.
  • Much of the damage caused by radiation exposure is caused by inflammation secondary to the effects of ionizing radiation itself known as Acute Radiation Syndrome.
  • Again, opaganib was not associated with a diminished tumor response to fractionated radiation treatment and increased weight loss from radiation treatment was not observed.
  • Data from the opaganib global Phase 2/3 study has been submitted for peer review and recently published in medRxiv .

RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022

Retrieved on: 
Wednesday, October 26, 2022

RALEIGH, N.C. and TEL-AVIV, Israel, Oct. 26, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the presentation of new data analyses for Talicia®, for the treatment of H. pylori, and Movantik®, for the treatment of opioid -induced constipation (OIC), at the American College of Gastroenterology Annual Meeting (ACG) October 21-26, 2022.

Key Points: 
  • This second Movantik poster evaluated the efficacy of Movantik in providing clinically meaningful symptom improvement, based on the PAC-SYM patient reported outcome, in patients with OIC.
  • In both analyses Movantik was well tolerated and demonstrated a favorable safety profile.
  • Talicia may affect the way other medicines work, and other medicines may affect the way Talicia works.
  • [11] The pivotal Phase 3 study with Talicia demonstrated 84% eradication of H. pylori infection with Talicia vs. 58% in the active comparator arm (ITT analysis, p

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Retrieved on: 
Tuesday, October 18, 2022

The Nasdaq letter is only a notification of deficiency and has no immediate effect on the listing or trading of the Company's ADSs.

Key Points: 
  • The Nasdaq letter is only a notification of deficiency and has no immediate effect on the listing or trading of the Company's ADSs.
  • RedHill's ADSs will continue to trade on the Nasdaq Global Market, and the Company's operations are not affected by the receipt of the Notice.
  • RedHill intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.

DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022

Retrieved on: 
Tuesday, July 12, 2022

Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: "We are looking back on an exceptionally successful first half of the year.

Key Points: 
  • Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: "We are looking back on an exceptionally successful first half of the year.
  • The Heidelberg Pharma Group (Heidelberg Pharma) comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH reports consolidated figures.
  • The net loss posted by the Heidelberg Pharma Group for the first six months of 2022 came to EUR8.6 million (previous year: EUR13.1 million).
  • In this respect, the full-year financial guidance issued on 24 March 2022 for the Heidelberg Pharma Group will not be adjusted at this time.

RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

Retrieved on: 
Friday, June 17, 2022

TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.

Key Points: 
  • TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.
  • The Company will host a conference call and webcast on Thursday, June 23, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the first quarter of 2022.
  • The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/events ,and will be available for replay for 30 days.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL ) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.

RedHill Presents New Talicia® Data Analyses at DDW 2022

Retrieved on: 
Wednesday, May 25, 2022

RALEIGH, N.C. and TEL AVIV, Israel, May 25, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the presentation of two new data analyses from the Talicia®H. pylori eradication clinical trials program at Digestive Diseases Week (DDW) 2022.

Key Points: 
  • pylori eradication clinical trials program at Digestive Diseases Week (DDW) 2022.
  • "More than 37 million Americans have diabetes, which presents significant issues in the treatment of H. pylori infection.
  • "Talicia consistently shows its ability to maintain high H. pylorieradication rates, even in challenging patient populations, with zero to minimal resistance.
  • In November 2019, Talicia was approved by the U.S. FDA for the treatment of H. pylori infection in adults.

RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

Retrieved on: 
Monday, April 11, 2022

TEL AVIV, Israel and RALEIGH, N.C., April 11, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640)1, a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability. Based on the new and previously announced data, opaganib's unique human host-targeted, dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations and remain effective against Omicron sub-variants BA.2, XE and other emerging and future variants.

Key Points: 
  • Opaganib was studied in a global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia (NCT04467840).
  • Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, with suggested dual anti-inflammatory and antiviral activity.
  • Opaganib is host-targeted and, based on data accumulated to date, is expected to maintain effect against emerging viral variants, having already shown in vitro inhibition against variants of concern, including Omicron and Delta.
  • All forward-looking statements included in this press release are made only as of the date of this press release.

DGAP-News: Heidelberg Pharma announces financial figures for fiscal year 2021 and provides business update

Retrieved on: 
Friday, April 1, 2022

The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.

Key Points: 
  • The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.
  • The Heidelberg Pharma Group recognized comprehensive income and a net loss of EUR -26.1 million (previous year: EUR -18.4 million) in the 2021 fiscal year.
  • These will primarily comprise the sales revenue generated by Heidelberg Pharma Research GmbH and, to a lesser extent, potential milestone payments to Heidelberg Pharma AG.
  • Financing requirements in the 2022 fiscal year for Heidelberg Pharma AG's business operations are expected to increase compared to 2021.

RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea

Retrieved on: 
Tuesday, March 15, 2022

TEL-AVIV, Israel, and RALEIGH, N.C., March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"), a South Korean corporation, for oral opaganib[1] for the treatment of COVID-19, in South Korea.

Key Points: 
  • TEL-AVIV, Israel, and RALEIGH, N.C., March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"), a South Korean corporation, for oral opaganib[1] for the treatment of COVID-19, in South Korea.
  • Kukbo will receive the exclusive rights to commercialize opaganib in South Korea for COVID-19.
  • Together with our partner, Kukbo, we are working hard to bring opaganib to Korean patients in need of new COVID-19 therapeutic options."
  • "With the data supporting opaganib for COVID-19, and the expanded partnership with RedHill, Kukbo is determined to work with local regulators with the aim of bringing opaganib to South Korean patients, as soon as possible."

RedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on March 17, 2022

Retrieved on: 
Thursday, March 10, 2022

TEL AVIV, Israel and RALEIGH, NC, March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights on Thursday, March 17, 2022.

Key Points: 
  • TEL AVIV, Israel and RALEIGH, NC, March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights on Thursday, March 17, 2022.
  • The Company will host a conference call and webcast on Thursday, March 17, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the fourth quarter and full year of 2021.
  • The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/events ,and will be available for replay for 30 days.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.